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1. INTRODUCTION  
 
In September 2015, the Council of the European Union adopted Council conclusions on the 
implementation of minimum quality standards in drug demand reduction in the EU. This innovative 
initiative lists 16 standards that represent a minimum benchmark of quality for interventions in: 
prevention, risk and harm reduction, treatment, social integration and rehabilitation. Although non-
binding for national governments, this document represents the political will of EU countries to 
address demand reduction interventions through an evidence-based perspective. 
 
Building on the insights gained from the assessment tool and feasibility study in the previous Civil 
Society Forum on Drugs (CSFD) project, the CSFD has developed the Guidelines and 
Recommendations for the implementation of Minimum Quality Standards in drug demand reduction 
in the European Union by Civil Society Organisations (CSOs)1. The aims of the guidelines and 
recommendations are to help and support CSOs working in the drug demand reduction field to: (1) 
assess and implement their interventions according to these standards; (2) identify potential barriers 
for incorporation; and (3) assess the potential need to provide training for practitioners and developers 
in the drug demand reduction field in line with these standards. 
 
The focus of the new CSFD project will remain further dissemination and promotion of guidelines and 
recommendations across Europe, advocacy for assessment and implementation of standards in 
practice, and development and testing of training course for CSOs to improve the implementation of 
standards within civil society sector. The key question which has to be answered in relation to the 
advocacy plan is on how to influence policy & decision makers at the European, national, regional & 
local levels to adopt & implement minimum quality standards in the field of drug demand reduction. 
 
One of the most important aims of the CSFD and especially its Working Group on Minimum Quality 
Standards in Drug Policy in the following years is to increase the quality of services in the area of drug 
demand reduction in the EU Member States by an active involvement of the Civil Society Organizations 
(CSOs). This will be achieved by promoting the implementation of minimum quality standards in EU 
Member States (advocacy) and improving knowledge and skills among CSOs on how to implement 
minimum quality standards on the national level (training). 
 
A comprehensive advocacy plan is prepared to support the promotion and implementation of the 
minimum quality standards in EU Member States and more specifically the guidelines and 
recommendations, which were developed and published in the previous CSFD project (2017-2019). 
The advocacy plan wants to stipulate all relevant advocacy actions and will address several key 
stakeholders and target groups, including policy and decision makers at the national and European 
level, and service providers and CSOs at the national level.  
 
The advocacy plan will be implemented in the period of 2020-2022 and includes specific activities, 
such as: (1) establishment of advocacy coalitions or alliances at national, regional or local level; (2) 
policy briefings with relevant stakeholders at EU, national, regional or local level (policy and decision 
makers); (3) media activities to inform different relevant stakeholders and target groups on existence 
and importance of minimum quality standards, assessment of implementation in reality and available 
training (which will be developed within this project as well); (4) promotion activities during relevant 
European conferences in the field of drug demand reduction (virtually or in-person depending on the 
COVID-19 situation) (e.g. European Society for Prevention Research (EUSPR) conference 2021, 
European Harm Reduction Conference (EHRC) 2021) through active participation and presentations; 
and (5) preparation of a thematic paper on minimum quality standards, focusing on the specific needs 
of marginalised (vulnerable) groups and gender-related issues which are not adequately addressed in 
the present Council Conclusions document (future considerations regarding standards). 
 
1 Link: https://info.harmreduction.eu/files/88/CEHRN/27/CSFD2020guidelinesrecommendationsENFINAL.pdf  
 
2. KEY TOPICS AND CHALLENGES FOR THE IMPLEMENTATION OF THE 
MINIMUM QULITY STANDARDS  
 
Based on the Guidelines and Recommendations, there are several key topics and challenges regarding 
minimum quality standards, which are important to highlight and which we recommend using in your 
advocacy plans at the first place: 
 
DISINVESTMENT FROM INEFFECTIVE AND HARMFUL INTERVENTIONS 
There are still many interventions in the field of drug demand reduction, which are not being carried 
out in line with minimum quality standards. Governments and civil society organisations should be 
aware of this and consciously seek to disinvest and moving support away from ineffective services and 
interventions. Correspondingly, they should invest more resources towards implementation of 
evidence-based and effective interventions, especially in the fields of prevention and risk and harm 
reduction. Advocacy activities should focus on the issues of promoting and enforcing the sustainable 
and long-term funding of evidence-based and effective interventions in the field of drug demand 
reduction. 
 
EDUCATION, TRAINING AND CONTINUING PROFESSIONAL DEVELOPMENT 
There is a gap in quality education and training for the drug demand reduction workforce (both in 
relation to basic training and in respect of continuing professional development). Governments and 
civil society organisations should investigate the long-term value of investment in this area, and look 
to invest more resources into developing and maintaining quality (formal and non-formal) education 
and training programmes for professionals and volunteers in the field of drug demand reduction. 
Advocacy activities should focus on the issues of investing in quality (formal and non-formal) education 
and training programmes in the field of drug demand reduction. 
 
MONITORING & EVALUATION 
The evaluation culture is weak in Europe in the field of drug demand reduction. There is little demand 
by (funding) authorities for monitoring and evaluation of programmes and other interventions 
(especially concerning outcome evaluation). Without evaluation there is impossible to say, which 
programmes and interventions are effective and has significant impact on the situation in the field of 
drug demand reduction. Governments and civil society organisations are advised to invest more in 
monitoring and evaluation, which would significantly improve the quality of interventions and 
motivation of professionals to continue with quality work. Advocacy activities should focus on the 
issues of promoting monitoring and evaluation as a criterion for sustainable and long-term funding 
and support from (funding) authorities. 
 
SUSTAINABLE FUNDING RELATED TO THE IMPLEMENTATION OF STANDARDS 
There is almost no sustainable funding for programmes and interventions in the field of drug demand 
reduction. States and funding bodies at all levels are advised to relate funding programmes and 
schemes to the implementation of minimum quality standards, but at the same time invest 
significantly more resources to improve the capacity of civil society organisations (technical and 
financial) to comply with those standards. Without sustainable funding, improved knowledge and skills 
of the workforce, and an improved monitoring and evaluation culture, we cannot expect significant 
improvements and developments in the field of drug demand reduction. Advocacy activities should 
focus on the issues of sustainable and long-term funding of evidence-based and effective programmes 




3. AIMS AND OBJECTIVE 
 
The aim of this advocacy plan is to support the promotion and implementation of the minimum 
quality standards in EU Member States and candidate countries and more specifically the guidelines 
and recommendations.  
 
This aims could be achieved by building European and national advocacy action plans, including the 
development of coalitions/alliances and specific advocacy activities, addressing pre-defined challenges 
(see Chapter 2 for the most relevant challenges according to the assessment of the implementation of 




1. Establishment of European advocacy coalition /alliance, which will include the most relevant 
European stakeholders for an action to promote the implementation of the minimum quality 
standards in EU drug policy and practice (e.g. representatives of CSFD and/or other relevant 
CSOs, academic and/or research networks or associations at EU level, media, policy and 
decision makers, and opinion leaders, such as MEPs, EC officials, national representatives in 
EU institutions etc.). 
 
2. Establishment of at least 4 national (or regional or local) advocacy coalitions / alliances, which 
will also mobilize the most relevant stakeholders for an action to promote the implementation 
of the minimum quality standards regarding national, regional or local drug policy and practice 
(e.g. representatives of relevant CSOs at national, regional and/or local level, academic and/or 
research institutions, media, policy and decision makers, and opinion leaders, such as MPs, 
public officials, representatives of political parties and other important interest groups etc.). 
 
3. Preparation and organisation of the policy briefings with relevant stakeholders (see above – 
point 1. and 2.) at EU, national, regional or local level (e.g. policy and decision makers). Each 
CSFD project partner or CSFD member organisation (involved in the implementation of this 
advocacy plan) will prepare and organise at least one meeting with relevant stakeholders 
(supported by a short policy brief) and promote the implementation of the minimum quality 
standards. 
 
4. Preparation and implementation of focused media activities to inform relevant stakeholders 
and target groups (e.g. those who are directly or indirectly involved in the implementation of 
minimum quality standards in drug demand reduction) on existence and importance of minimum 
quality standards, assessment of implementation in reality, and available training on how to 
implement the minimum quality standards (which will be developed within this project as well).  
 
5. Preparation and implementation of promotion activities during relevant European 
conferences in the field of drug demand reduction (e.g. European Society for Prevention 
Research (EUSPR) conference 2021, European Harm Reduction Conference (EHRC) 2021) 
through active participation and presentations (virtually or in-person depending on the COVID-
19 situation); and  
 
6. Preparation of a thematic paper on minimum quality standards, focusing on the specific needs 
of marginalised (vulnerable) groups and gender-related issues which are not adequately 
addressed in the present Council Conclusions document (future considerations regarding 
standards). 
 
4. TARGET GROUPS 
 
Our main target group are decision-, opinion- and policy-makers (DOPs), who are the most relevant 
regarding the implementation of minimum quality standards in policies and practice, and (directly or 
indirectly) evidence-based drug demand reduction services and interventions. This group, which we 
refer to as »drug demand reduction professionals«, includes drug demand reduction coordinators at 
the ministries, state agencies, regional and local authorities etc., drug demand reduction specialists 
and policy-makers with both general and specialist roles that include responsibility for drug demand 
reduction programmes and their funding.  
 
At the European level, our target groups could be as follows: representatives of CSFD and/or other 
relevant CSOs, academic and/or research networks or associations at EU level, media, policy and 
decision makers, and opinion leaders, such as MEPs, EC officials, national representatives in EU 
institutions etc.). At the national, regional and/or local level, our target groups could be as follows: 
representatives of relevant CSOs at national, regional and/or local level, academic and/or research 
institutions, media, policy and decision makers, and opinion leaders, such as MPs, public officials, 
representatives of political parties and other important interest groups etc.). 
 
In some countries, this group may also include senior practitioners who are influential in decision-
making and professional development. They can be located at the European, national, regional, or 
local level. They may be heads of civil society organisations (CSOs) engaged in delivering drug demand 
reduction services and interventions, drug demand reduction coordinators in a regional or local 
administration, civil servants who develop strategies and action plans and commission drug demand 
reduction interventions at the regional or local level, stakeholders or part of community coalitions or 
action teams/groups in the field of drug demand reduction etc. (adapted from European Prevention 
Curriculum, 2019). 
 
Finally, our target group are also other civil society organisations (CSOs) which might benefit from our 
case studies of advocacy action in different countries (e.g. to learn from those examples for their own 
actions in the future). 
 
5. ACTION PLAN  
 
IMPORTANT NOTE: Each national, regional or local coalition or alliance (established in the participating 
country, at least in Spain, Finland, Hungary and Slovenia) could choose one of more standard(s) or 
topic(s) or challenge(s) related to the minimum quality standards described in the CSFD Guidelines 
and Recommendations by itself. It depends on the expertise, preferences and experience of the 
coordinator (CSFD member) and its coalition / alliance in the field of drug demand reduction 
(prevention, risk and harm reduction, treatment, social integration and rehabilitation or recovery). The 
action plan is divided in two parts: the European action plan and at least 4 national, regional and/or 
local action plans in Hungary, Finland, Spain and Slovenia. 
 
As mentioned, this advocacy plan will be implemented at two levels: 
 
• European level (coordinated by UTRIP & in partnership with CSFD Members) 
• National (or regional or local) level (coordinated by selected CSFD Members themselves in their 
own countries, regions or local communities) 
 
In the following table, an initial plan is presented (a minimum set of activities per participating partner) 
(see Table 1 and 2), but coalitions / alliances are free to add more activities and outputs: 
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assessment and 
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plan for EU-wide 
advocacy 
campaign  
1. Coalition / alliance 
develops its own 
advocacy action 
plan (using the 
hints & questions 
in the table 
below). 
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(including Core 
Group calls)  
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EU (e.g. policy & 
decision makers) 
1. Coalition / alliance 
prepares and 
organises at least 
one meeting with 
relevant 
stakeholders at 
the EU level 
(supported by short 
policy brief)  
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implementation 
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contribution of all 
coalition / alliance 
partners 
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coalition / alliance 
partners (could also 
be led by the 
partner who is 
responsible for 
media advocacy 
part of the action 
plan) 
A set of media 
activities (at 
least  1 x press 
release, 1 x press 
conference if 
possible, 3 x 
website news and 
5 x social media 
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regional, or local 
coalition / 
alliance 
1. Establish coalition 
/ alliance using 
step-by-step 
model explained 
in the Chapter 6. 




3. Conduct a needs 
assessment and 
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should be 
established in at 
least 4 countries 
(Slovenia, Spain, 
Finland and Hungary) 
by CSFD Members 
in those countries 
(but not limited to 





















plan for your 
advocacy 
campaign  
1. Coalition / alliance 
develops its own 
advocacy action 
plan (using the 
hints & questions in 
the table below). 
2. Consultations 
with UTRIP       
(WP leader)  




4. Prepare case 
study reports 
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(e.g. policy & 
decision makers) 
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prepares and 
organises at least 
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1. Coalition / alliance 
prepares & 
implements a set 
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the national, 
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level on existence 






CSFD Member in 
collaboration with 
coalition / alliance 
partners (could also 
be led by the 
partner who is 
responsible for 
media advocacy 
part of the action 
plan) 
 
All CSFD Members 
could also send the 
prepared media 
materials to their 
national, regional or 
local media 
(translated & adapted 
to their context) 
A set of media 
activities (at 
least  1 x press 
release, 1 x press 
conference if 
possible, 3 x 
website news and 
5 x social media 





methods on how 
to use media in 
advocacy & hints 




Each partner (coalition / alliance) in this CSFD initiative shall prepare its own advocacy (action) plan 
and follow the steps or answer the questions explained in the table below (see Table 3): 
 
Table 3: Preparation of advocacy (action) plan (hints and questions) 
 
Steps Hints Questions to be answered 
1. Aims and objective(s) It is recommended that you 
choose very specific objective (not 
too wide / general), which is more 
feasible to be achieved in very 
short time of action. 
What do you want to achieve 
with advocacy plan? 
 
2. Create coalition / alliance Do not create too large coalition 
or alliance (e.g. up to 10 
members), otherwise you could 
have problems with managing the 
group and tasks. 
Who do you want to involve in 
coalition / alliance & why? 
Distribute the tasks! 
3. Target group(s) (public 
audience) 
It is highly recommended that 
your audience is not too large (do 
not choose too many target 
groups). It’s better to decrease 
the ambition sometimes to 
achieve goals step-by-step. 
Who is (are) your target 
group(s) or audience, which 
you want to reach & influence? 
 
 
4. Message(s) It is more likely that you will get 
attention from target group(s) or 
media if you create a bit 
provocative message. If possible, 
focus on positive messages and 
avoid criticism or negativism. 
What is your message? Do you 
have one message for more 
target groups or more 
messages for more target 
groups or more messages for 
one target group? 
5. Products & materials Do not produce too long materials 
(e.g. alongside the press release), 
especially for policy and decision 
makers (up to 5 pages would be 
enough if you want that your 
audience will read them). 
What kind of (media) products 
& materials are you going to 
produce to place your 
message(s) in the easiest way? 
6. Channels Do a good assessment of the 
target group(s) and find out which 
communication (media) channels 
are more often used by them. And 
use them too in your actions. 
How (through which channels) 
are you going to promote & 
disseminate your message(s) 
and (media) products? 
7. Responses (feedback) Follow and monitor (e.g. 
document) all responses and 
feedback from target group(s) and 
media and try to find out if you 
were successful with the media 
coverage and creating adequate 
political or media attention. 
Will your media action 
influence target group(s)? How 
are you going to evaluate if 
you were successful with 
(media) action? 
 
6. IMPLEMENTATION OF THE ADVOCACY PLAN AND COVID-19 
 
Due to COVID-19 situation and limitations to organise meetings and conferences in person, CSFD 
Members involved in the implementation of this advocacy plan are advised and should have a plan to 
organise virtual meetings (e.g. coalition kick-off meeting, CSFD Core Group calls and other meetings) 
and conferences (e.g. with key stakeholders in the field) when and where necessary (by using virtual 
platforms such as Zoom, MS Teams, GoToMeeting, Skype etc.). The activities and outputs of this 
advocacy plan regarding the promotion of the implementation of minimum quality standards could 
also be conducted online, by submitting abstracts and presenting the results at the international or 
national conferences which will be organised on virtual platforms.  
 




Advocacy skills are essential for the public health scientists, researchers, and practitioners to 
potentially influence policy- and decision-making processes for better health-related policies and 
practice. Those skills are important especially in those public health areas where so-called »unhealthy« 
industries are influential and/or (at least) want to be important stakeholders in the field (such as 
alcohol, tobacco, and cannabis industry). They are also important to advocate for evidence-based 
substance use policy (e.g. alcohol, tobacco, or illicit drug policy) and implementation of evidence-based 
interventions in the field of drug demand reduction which should be fully in line with minimum quality 
standards. 
 
Advocacy may include activities and actions by individual or group with the intention of influencing 
policy- and decision-making processes and resource allocation decisions and with the aim of 
developing, establishing or changing policies and practices and of establishing and sustaining evidence-
based programmes and services and their funding. Advocacy can include many activities including 
media campaigns, public speaking, commissioning, and publishing research or polls or the filing of 
amicus briefs, additional arguments, amendments and complaints, lobbying, social marketing etc. 
 
People often mix advocacy, lobbying and social marketing. Educating the legislature on a particular 
issue is generally considered advocacy, while pushing a particular vote on a particular law is generally 
considered lobbying. Social marketing seeks to develop and integrate marketing concepts with other 
approaches to influence behaviours that benefit individuals and communities for the greater social 
good. 
 
Investing in knowledge and skills in advocacy is particularly important, especially for the civil society 
organisations (CSOs). That may (potentially) increase competence on: (1) forging stronger relationships 
with policy and decision makers and other important key stakeholders in the field of drug demand 
reduction; (2) advocating for the use of research to inform policy and decision makers about evidence-
based substance use (e.g. drug) policies and practices, and research funding priorities; (3) providing 
expert testimony (e.g. in the parliament); (4) writing position papers, press releases and social media 
posts, organising press conferences etc.; (5) increasing the visibility and recognition of evidence-based 
substance use (e.g. drug) policies and practices; and (6) committing to ongoing advocacy (as a regular 
part of our daily work). 
 
BUILDING EFFECTIVE COALITIONS/PARTNERSHIPS FOR ACTION  
 
One of the most important steps in advocacy planning is to build effective coalition or alliance 
(partnership for action at European, national, regional and/or local level). Coalition is usually informal 
(ad hoc, focused on one single problems or challenge etc.) and alliance is usually formal (e.g. 
established entity with staff, office(s), decision-making structure, focused on ongoing advocacy etc.). 
 
What is an advocacy coalition or alliance? It is a group of people, countries or stakeholders that join 
for a common purpose. When building a coalition/alliance, these groups agree on behaving and 
working cooperatively towards a set of joint actions defined within the group (APYN, 20142). 
 
Building a successful coalition implies a series of steps, namely: (1) setting common and compatible 
goals; (2) mutual benefits of co-working and (3) assuring that the benefits are surpassing the costs. 
Benefits of coalitions/alliances are especially increasing the potential of success, empowering the 
 
2 Link: https://www.apyn.org/data-si/file/APYN_Triangle.pdf  
 
weaker member to have more influence on the matter and concentrating expertise and resources to 
deal with complex issues and attracting media attention. However, there are also some disadvantages 
of coalitions/alliances, such as overworking, different levels of resources and interests, and different 
levels of credit. When choosing the members of a coalition or building a coalition, attention should be 
drawn to the organisation’s goals and interests, otherwise we could experience many problems like in 
any other relationship with people or organisations with different goals and interests. 
 
Each participating partner shall establish / build its own coalition or alliance to carry out the advocacy 
activities regarding the implementation of minimum quality standards in their own country, region, or 
local community. Based on the chosen topics or challenges, partners invite coalition members to join 
the coalition. In addition, a European coalition or alliance will be established to promote the 
implementation of minimum quality standards at the European level (led by UTRIP in collaboration of 
CSFD Core Group). There are several potential partners or members of coalition / alliance which they 
have to take into consideration (see Figure 1). 
 




Choosing the members of a coalition / alliance or building a coalition / alliance should focus on the 
organizations’ goals and interests. Therefore, partnering up with different parties needs time and 
commitment that can lead to big successes or bitter endings. The main stakeholders in drug (or wider 
substance use) policy with whom you should or shouldn’t partner up to achieve your advocacy goals 
includes: 
 
• Civil society organisations (e.g. in the field of drug demand reduction) 
• Researchers / scientists (e.g. universities, research institutes) 
• Health, social and other drug-related services (especially at local level) 
• Policy- and decision-makers (e.g. representatives of the EU institutions, ministries and 
state agencies in the field of health, interior, justice etc., members of the committees or 
commissions in the parliament or local councils, local / city mayors and representatives of 
the municipality or city authorities, representatives of relevant European institutions etc.) 
• Media representatives (e.g. journalists or editors who can help us with media advocacy, 
contacts with other journalists, preparation of press materials, such as press releases, 
























Civil society (NGOs, 







Each project partner is recommended to use the following step by step approach in the process of 
building/sustaining a national, regional or local coalition or alliance (adapted from APYN): 
 
• STEP 1: SELF-ASSESSMENT 
 
o Identify your own goal (see the Guidelines & Recommendations3) 
 
It is important that your main aim and specific objectives regarding the promotion and 
implementation of minimum quality standards in drug demand reduction are measurable and 
realistic. In order to reach them, put a figure, value or percentage to each aim or objective. For 
instance, if you want to increase the funding for evidence-based interventions, you should define 
the exact percentage of how much it should increase. 
 
o Make a decision of the need to form a coalition / alliance 
 
The establishment of a coalition / alliance should be well thought out. Maybe you have enough 
resources and expertise to reach your goals on your own or maybe you are lacking something. 
Nevertheless, you should never forget that in many cases, coalitions / alliances are significantly 
more successful than a single organization or individual. 
 
• STEP 2: IDENTIFY THE POSSIBLE PARTNERS / COALITION MEMBERS 
 
o Make a list of possibilities 
 
Firstly, consider organizations, institutions, media and even individuals (e.g. experts) who share 
the same or similar interests as you do and support your goals regarding the implementation of 
minimum quality standards. Also, you should think of different possible allies, because a group of 
organizations and institutions from a diverse background is more likely to succeed. 
 
o Know all about them 
 
Once you have identified organizations, institutions, media and individuals with similar goals, 
analyse them. Get to know the projects the organizations and institutions are working on, the 
projects they previously worked on, and how the organization or institutions may fit within your 
advocacy campaign. 
 
o Remember to avoid conflict of interest 
 
Always remember the coalition’s or alliance’s interests, do not create a coalition or alliance for an 
individual purpose. You should also deeply analyse your partners and know their personal interests 
to make sure they are not against or significantly differ from the main aim and objectives of a 
coalition / alliance and its goals in the campaign regarding minimum quality standards. 
 
• STEP 3: TAKE THE FIRST STEP 
 
Run a meeting or event for everyone (could be online due to COVID-19 situation) who has enlisted in 
a coalition / alliance to meet each other. Allow each and every organization, institution or individual 
to talk about their projects or campaigns and discuss which could be the added value of being part of 




3 Link: https://info.harmreduction.eu/files/88/CEHRN/27/CSFD2020guidelinesrecommendationsENFINAL.pdf  
 
• STEP 4: IDENTIFY A COMMON AIM AND COMPATIBLE INTERESTS 
 
Recognise compatible interests once you have identified an issue. In order to work together, agree on 
a common goal regarding the implementation of minimum quality standards (see the Guidelines and 
Recommendations) and make the aim or objective clear for all the members of the coalition / alliance. 
It is also possible that within the coalition / alliance some organizations also have other parallel 
interests. In order to make the coalition / alliance work, focus the work on the common ones! 
 
• STEP 5: NEEDS ASSESMENT 
 
It is of great importance to assess the needs of the coalition / alliance in order to accomplish the goals 
previously defined by all the partners. Analyse which measures the coalition / alliance should take and 
what resources are necessary to take the outlined steps. 
 
• STEP 6: DEFINE ROLES OF EACH COALITION PARTNER 
 
Ensure that each partner is motivated to contribute, being not only aware of what his role would be, 
but also comfortable with it and willing to do a good job. Each coalition partner should recognize the 
roles of all partners within the coalition / alliance and understand how this engagement is productive 
for the coalition / alliance. Nevertheless, it might be more effective to have a partner whose role is 
also to coordinate the work of the coalition / alliance (e.g. in our case this is meant to be a role of the 
CSFD Core Group, CSFD members or project partners), especially if there are many partners involved. 
 
• STEP 7: DEFINE THE RULES ON COMMUNICATION AND RESPONSIBILITIES 
 
For the partners to execute their roles adequately, the coalition / alliance must define rules of 
functioning/communication and the responsibilities that each partner must accomplish. 
 
Define exactly what the work plan is (topics, (virtual) meeting plans, deadlines, reports, etc.) and who 
is taking responsibility for each part of it. As with the roles, if each other’s roles and responsibilities are 
clear for the whole coalition / alliance, the partners are able to ensure that each member follows what 
was decided by all of them and the coalition will work more efficiently. 
 
Remember to recruit the right people within each partner organizations or institution bearing in mind 
what the ideal profile would be. 
 
• STEP 8: STRATEGIC AND OPERATIONAL PLANNING 
 
Defining the strategic and operational planning is a task that needs to be done by the whole coalition 
/ alliance, as all the partners need to identify their participation in the coalition / alliance in these 
orientation documents. As a group, the coalition / alliance needs to define how the goals will be 
achieved through a defined action plan. 
 
Evaluate the resources each partner has (human, financial, time, material etc.) and which resources 
each of them need, in order to fulfil their responsibilities. Solutions for each other’s needs can, 
sometimes, be found within the coalition / alliance. 
 
Define specific objectives and what the expected results are matching the goals. Also, what are the 
activities designed to accomplish each of the goals defined. This data must be measurable and have 





• ONGOING: MONITORING AND EVALUATION 
 
Monitor and evaluate the implementation of your operational planning and reflect on how it matches 
this strategic advocacy plan. Adapt the plan if needed. 
 
Provide regular meetings for the partners to communicate in person or via remote communication 
platforms (e.g. Zoom, GoToMeeting, MS Teams etc.) if the situation with COVID-19 does not allow 
meetings in person, but assure that the work that is being done is reported to the coalition / alliance 
by all partners, using the communication rules defined. 
 
Create clear deadlines and emphasize the need to follow them as well as to commit with the steps 
taken and do the necessary preparations.  
 
Even though the coalition / alliance might have a leader responsible for coordinating the work, it is all 
partners’ responsibility to actively be involved in the entire action plan. 
 
To reinforce this, consider rewarding the included partners and the individuals representing the 
organizations or institutions. Depending on the formality of the coalition / alliance, it can be useful to 
provide a teambuilding programme, developing bonds within the coalition / alliance and self-
accomplishment for being part of it. 
 
KEY MESSAGES (MAKING THE CASE WITH MEDIA ADVOCACY) 
 
Media coverage is one of the best and most effective ways to draw attention amongst decision-, 
opinion- and policy-makers etc. With good message is rather easy to draw media attention and 
coverage. 
 
Before action we need good media plan (as a part of comprehensive advocacy plan) and proper 
message. Some key questions we have to answer in this process of key messages development: (1) 
What is a problem and what are possible solutions?; (2) Who could put those solutions into effect?; 
and (3) What should we do or say to draw attention of those who could put solutions into effect? 
 
In addition, we need to prepare a list and contact information on media, journalists, editors etc. which 
are important for our action. Before we establish contacts with them, we have to prepare a good 
message or more messages (if we target more audiences), distribute the roles and tasks within the 
coalition / alliance, select the speaker(s) and/or reporter(s) and prepare all relevant materials, list of 
sources and information in advance. 
 
There are several effective methods of using media in advocacy, which you can plan in the preparation 




• PRESS RELEASES 
 
A good press release usually includes: name of organisation, contact information, date of release, title 
(important, could be provocative) and main content (who, what, where, when, and why). Regarding 
the main content, the most important information should be on the top. First paragraph is the most 
important. Use short paragraphs / sentences and simple language. Use of citations / quotations are 
highly recommended (e.g. prepare quotations from your advocacy campaign partners in advance and 
include them already in the press release). 
 






• CORRESPONDENCE COLUMNS / BLOGS 
 
In recent years, blogs are becoming popular way of communicating with general public. 
Correspondence columns are also still popular in traditional newspapers and lots of readers actually 
read them if the topic is of their interest. We use those methods particularly in polemics, pro et contra 
discussions and we can cover more media with them at the same time. Shorter notes or columns are 
more effective (e.g. 250-300 words). You should be aware on criteria and rules for publication, limits, 
special editorial rules etc. If possible, attach your note, column or letter to other previously published 
related articles and stories. It is also important that you introduce yourself (name, contact 
information), so readers or journalists can refer particular topic or content to you and your 
organisation, institution, or coalition / alliance. 
 




• INTERVIEWS, TV AND REDIO DISCUSSIONS 
 
Many drug policy professionals, advocates and activists are already rather experienced in using TV and 
radio in their own advocacy campaigns. If you are not sure that you are capable to do it (e.g. no 
experience yet), you can always recruit somebody else in the coalition / alliance with more experience 
with media. If you are not invited to speak on the TV or radio, try to »invite« yourself (especially if you 
know that some interesting debates are going to happen on TV or radio regarding drug policy etc.). 
Inform yourself on concept and host of the talk show, names of other guests (and their arguments and 
positions), programme and characteristics of discussion etc. Prepare yourself for interviews and 
discussions in advance. During interviews and discussions speak clearly, plainly, avoid slang, 
abbreviations, expose key message first, be short, concise etc. 
 
 
• PRESS CONFERENCE(S)  
 
Press conferences could be formal or informal. They enable direct contact and communication with 
journalists. Organise it only for larger events, milestones, publication releases (e.g. case study report) 
etc. Some hints: be aware of the location (e.g. parking and close to the most important media houses), 
timing (e.g. up to one hour at the most), informing media in advance (e.g. sending invitation a day or 
two before the press conference), preparing press release and other materials in advance (so you can 
deliver them at the press conference and send to other media after it), preparation activities (e.g. 
communication with press conference facility staff, technical support etc.), interviews after the event 
(e.g. make sure there is enough time for interviews and space for cameras etc.), contact details for 
additional questions etc. 
 
• SOCIAL MEDIA POSTS 
 
Social media are more and more important in advocacy. Unhealthy industries use them all the time, 
so we have to use them as well. If we have resources, it is a good idea to use Facebook or Twitter Ads 
promotion (payable, but cheap). Especially Twitter is growing fast as a communication channel 
(especially among policy and decision makers), so we recommend you to learn how to use it in the 
most effective way. Important: if you are not in (social) media, you do not exist. 
 
Figure 4: There are many options to communicate in social media 
 
 
 
 
 
 
 
 
